Phase Ib Expansion Study of CX-5461 in Patients with Solid Tumours and BRCA2 and/or PALB2 Mutation
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials.
Primary Objective: To further determine the recommended phase II dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected advanced solid tumours. Secondary Objectives: * To assess the safety and tolerability of CX-5461, in particular to determine late onset toxicity (ocular toxicity). * To evaluate the anti-tumour activity of CX-5461 in patients with solid tumours and germline BRCA2 and/or PALB2 mutation. * To evaluate the effect of CX-5461 on Health Related Quality of Life (HRQoL)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.